EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting

EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following upcoming conferences:

Citi 2026 Biopharma Back to School Conference Forum: Fireside Chat Date: September 9, 2026 Time: 8:00 am ET

Cantor Global Healthcare Conference 2026 Forum: Fireside Chat Date: September 10, 2026 Time: 10:20 am ET

Morgan Stanley Global Healthcare Conference Forum: Fireside Chat Date: September 15, 2026 Time: 7:00 am ET

A webcast and subsequent archived replay of each fireside chat at the Investor Conferences may be accessed via the Investors section of the Company website at www.eyepoint.bio .

Scientific Meeting EyePoint will be participating at The Retina Society 59th Annual Scientific Meeting from September 23-26, 2026, in Los Angeles, CA.

Presentation: Bioerodible EYP-1901 (Vorolanib Intravitreal Insert) for Sustained Release of a Tyrosine Kinase Inhibitor for Retinal Exudative Disease: Mechanism of Action and Pharmacokinetic Characteristics Presenter: Ehsan Rahimy, M.D. Date & Time (Session): September 24, 2026 | 11:15 AM PT (AMD I)

Presentation: LUGANO Phase 3 Trial of Bioerodible EYP-1901 (Vorolanib Intravitreal Insert) vs Aflibercept in Patients with Neovascular Age-Related Macular Degeneration (nAMD): First-Time Vision and Anatomic Outcomes Presenter: Carl D. Regillo, M.D., FACS, FASRS Date & Time (Session): September 24, 2026 | 11:18 AM PT (AMD I)

Presentation: LUGANO Phase 3 Trial of Bioerodible EYP-1901 (vorolanib intravitreal insert) vs Aflibercept in Patients with Neovascular Age-Related Macular Degeneration (nAMD): First-Time Safety and Treatment Burden Outcomes Presenter: Charles C. Wykoff, M.D., Ph.D. Date & Time (Session): September 24, 2026 | 11:23 AM PT (AMD I)

Presentation: Association Between Central Subfield Thickness (CST) Fluctuation and Visual Acuity (VA) Outcomes in Patients with Neovascular Age-Related Macular Degeneration (nAMD): An IRIS ® Registry Analysis Presenter: Durga S. Borkar, MD, MMCi Date & Time (Session): September 25, 2026 | 3:45 PM PT (AMD III)

Presentations from The Retina Society will be available in the Scientific Publications section of the Company website at www.eyepoint.bio .

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

The Company is committed to partnering with the retinal community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU ™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors: Robin Garner EyePoint, Inc. [email protected]

Media: Helen O’Gorman FTI Consulting [email protected]